What do systematic reviews say?

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  RR 19.45 [8.6, 43.99]
  4 studies · 575 participants
  Moderate

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  OR 3.62 [1.5, 8.74]
  8 studies · 1390 participants
  Moderate

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher physician assessment of success compared with placebo (moderate certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  RR 17.1 [10.07, 29.05]
  7 studies · 1339 participants
  Moderate

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  RR 1.14 [0.89, 1.45]
  8 studies · 1388 participants
  Low

Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo

• Botulinum toxin type A for facial wrinkles 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 77 participants
  Moderate